398 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 12,752 published Tirzepatide COA source records from third-party laboratories, covering 1,778 publicly attributable vendor identities. Across 11,832 records with positive numeric purity, the arithmetic mean is 99.68%. 143 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 25 positive purity results are below 90%; 598 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.50 | $5.50–$7.50 | $1.30 | 2 sources · 2 offers |
| 10 mg | $8.88 | $8.00–$9.50 | $0.89 | 4 sources · 4 offers |
| 15 mg | $9.67 | $8.50–$10.50 | $0.64 | 3 sources · 3 offers |
| 20 mg | $11.33 | $10.50–$12.00 | $0.57 | 3 sources · 3 offers |
| 30 mg | $15.00 | $12.50–$17.00 | $0.50 | 4 sources · 4 offers |
| 40 mg | $19.88 | $18.00–$23.00 | $0.50 | 4 sources · 4 offers |
| 50 mg | $22.25 | $22.00–$22.50 | $0.45 | 2 sources · 2 offers |
| 60 mg | $26.12 | $25.00–$27.50 | $0.44 | 4 sources · 4 offers |
| 100 mg | $35.00 | $35.00–$35.00 | $0.35 | 1 source · 1 offer |
| 120 mg | $37.00 | $37.00–$37.00 | $0.31 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-19T04:35:51.231648+00:00. Calculation time is not a laboratory observation date.
Within that total, 3066 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 241 | 99.6% | 0 of 229 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #2 | 195 | 99.53% | 0 of 183 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #3 | 136 | 99.78% | 0 of 96 (0.0%) 0 0% / not detected · 0 wrong compound · 40 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120707 (99.88%) · #120652 (99.93%) · #120647 (99.96%) · #120646 (99.94%) · #120632 (99.9%) · #120622 (99.91%)
A prospective pilot study explores if GLP-1 RAs improve pain, disability, and quality of life in obese adults with chronic low back pain.
**Improving the reliability and accuracy of biomedical knowledge graphs** is paramount for accelerating critical processes in drug discovery, target identification, and the advancement of personalized medicine. By pre…
**Clinicians prescribing GLP-1 receptor agonists should be aware of a potential association with increased rates of upper eyelid blepharoplasty**, and consider discussing this with patients, particularly those with co…
Tirzepatide shows promise for managing **obesity** and maladaptive behaviors in a **31-year-old female** with **Smith-Magenis syndrome**, highlighting its potential beyond typical applications.
For individuals with **Type 1 Diabetes (T1DM)**, **tirzepatide** could represent a significant adjunctive therapy, offering improved glycemic control and substantial reductions in daily insulin dosage. **This could le…
This real-world data suggests that **tirzepatide** can be a valuable component of a comprehensive metabolic management strategy for patients with **psoriasis** and **obesity**. The observed improvements in weight, glu…
A Phase 2 trial will evaluate **tirzepatide** in Wolfram Syndrome Type 1 patients to increase endogenous insulin and correct glycemic lability.
This real-world data from an Indian cohort provides crucial insights for **personalizing GLP-1/GIP agonist therapy** and managing patient expectations. The finding that **tirzepatide** leads to greater weight loss tha…
Tirzepatide reduced 1-year venous thromboembolism risk by **10%** (HR **0.90**, p=**0.011**) and pulmonary embolism by **12%** (HR **0.88**, p=**0.021**) compared to GLP-1 RAs in **701,374** obese patients.
This study suggests a potent new strategy for managing **PCOS** in overweight/obese women, particularly those struggling with weight loss and fertility. **Combining low-dose tirzepatide with metformin offers superior …
This study provides compelling evidence that **tirzepatide offers comprehensive cardiovascular risk reduction beyond its established benefits in weight loss and glycemic control**. The significant, dose-dependent impr…
Adolescents and young adults (AYAs) and their caregivers face complex decisions regarding weight loss medications, experiencing reduced appetite and improved well-being, alongside stigma.
This direct comparative trial is crucial for optimizing **incretin-based pharmacotherapy** for obesity and metabolic syndrome. By meticulously quantifying differences in adipose remodeling, liver fat reduction, and ov…
If successful, this trial could establish **tirzepatide** as a novel, dual-action therapeutic for **smoking cessation**, particularly beneficial for people who smoke with **overweight or obesity**. This could offer a …
This study provides crucial real-world evidence for clinicians, especially anesthesiologists, to optimize perioperative patient management. **Early recognition of drug-related IGE** is now better supported, allowing f…
Achieving a lower BMI category with **tirzepatide** translates into clinically meaningful improvements in a wide array of cardiometabolic risk factors, reinforcing its potential to profoundly impact **obesity** manage…
Understanding the precise molecular mechanisms of **GLP-1R agonists** and dual **GIPR/GLP-1R agonists** in human adipocytes is crucial for optimizing their therapeutic potential beyond weight loss. **Future research s…
This large-scale pharmacovigilance study provides reassuring real-world safety data for GLP-1 RAs, suggesting they do not carry a disproportionate risk of thrombotic events. **This finding reinforces the favorable saf…
This research significantly expands our understanding of tirzepatide's mechanism of action, revealing its ability to activate brown adipose tissue and boost energy expenditure, beyond its known effects on appetite and…
A study will evaluate Bimagrumab and Tirzepatide, alone or combined, for efficacy and safety in adults with obesity or overweight without Type 2 Diabetes.
This case report highlights a previously undescribed adverse event profile for **tirzepatide**, particularly when combined with calcium supplementation. **Clinicians must closely monitor patients' electrolytes, especi…
This review underscores a significant paradigm shift, suggesting that **GLP-1RAs**, commonly used for diabetes and obesity, could offer a novel therapeutic avenue for chronic inflammatory skin diseases. For peptide us…
Study to assess if weight loss, potentially with **GLP-1 receptor agonists**, improves **plaque psoriasis** treatment efficacy in overweight/obese Chinese patients.
**This study highlights a critical safety concern for individuals using tirzepatide who require anesthesia.** If the hypothesis is confirmed, current pre-anesthetic fasting guidelines may be insufficient for **tirzepa…
A Phase 1 pilot trial is underway to assess tirzepatide's effects on colorectal cancer risk biomarkers and evaluate the feasibility of precision prevention.
This real-world study will provide critical insights into **tirzepatide's effectiveness and safety profile** in a specific Latin American population, which can significantly influence clinical practice in Paraguay and…
**If successful, this study could establish a novel pharmacological approach for managing Alcohol Use Disorder (AUD)**, potentially offering a new treatment option for individuals struggling with alcohol cravings. Und…
This meta-analysis provides crucial reassurance for clinicians and patients regarding the short-to-medium term safety of incretin-based therapies concerning **thyroid cancer** risk. **For individuals using or consider…
The widespread use of `GLP-1 RAs` demands a paradigm shift in clinical practice to safeguard patient mental health. **Routine eating disorder screening before and during GLP-1 RA treatment is now critical**, along wit…
This research unveils a novel mechanism by which **GIPR** and **GLP-1R** agonists, including dual agonists like tirzepatide, could modulate dopamine signaling in brain regions critical for reward and addiction. **The …
This case report underscores the clinical relevance of the FDA black box warning for GLP-1 receptor agonists like **tirzepatide** regarding **medullary thyroid cancer (MTC)** risk. While a single case cannot establish…
This case underscores the extreme complexity and high recurrence rate associated with massive **Type IV hiatal hernias**, particularly when compounded by multi-organ involvement and patient comorbidities. For clinicia…
**This comprehensive analysis reinforces GLP-1-based therapies as a cornerstone for managing Type 2 Diabetes with cardiovascular risk.** It provides critical agent-level insights, guiding clinicians in selecting speci…
This real-world data from Japan reinforces the robust efficacy of **tirzepatide** beyond controlled trial settings, providing crucial validation for its use in diverse patient populations. **For clinicians and patient…
This network meta-analysis provides crucial, evidence-based guidance for clinicians and individuals navigating the expanding landscape of anti-obesity medications. **Tirzepatide 15mg** and **CagriSema** are now clearl…
This meta-analysis provides crucial insights for individuals using GLP-1RAs for weight management, particularly those concerned about body composition. **While GLP-1RAs are highly effective for fat loss, strategies to…
Dual `GIP`/`GLP-1` agonist **tirzepatide** achieved MACE non-inferiority vs. dulaglutide, slowed `eGFR` decline in **T2D**, and reduced heart failure events in **obesity** with `HFpEF`.
GLP-1 receptor agonists significantly reduced the risk of postoperative inflammatory complications like infection and wound disruption after dermatologic surgery.
Given the escalating use of **GLP-1RAs** for metabolic conditions and weight management, **dermatology practitioners and prescribing clinicians must be acutely aware of the potential association with alopecia**. This …
This review highlights that while **GLP-1 RAs** are not yet proven as direct treatments for lipedema progression, they hold significant promise as **adjunctive therapies**. For individuals with lipedema, who often str…
The comprehensive metabolic improvements observed with tirzepatide represent a significant leap forward for individuals managing **type 2 diabetes** and associated **cardiovascular risks**. **This dual GIP/GLP-1 agoni…
This meta-analysis provides critical head-to-head evidence for clinicians and individuals managing **obesity** and **type 2 diabetes**. **Tirzepatide offers superior weight loss compared to semaglutide**, which could …
This research offers a transformative approach to managing **obesity** and **Type 2 Diabetes** by potentially enabling dramatically less frequent dosing. **Patients could achieve sustained weight and glucose control w…
This head-to-head **tirzepatide** vs. **semaglutide** trial is crucial for clinicians and individuals seeking optimal pharmacotherapy for **obesity** and **overweight**. While both are highly effective, a direct compa…
A 52-week randomized controlled trial will assess **Tirzepatide** with a culturally-tailored intensive lifestyle intervention in Latino adults with obesity.
GLP-1 receptor agonists' pleiotropic effects on retinal microvasculature are reviewed, highlighting their potential to mitigate diabetic microangiopathy beyond glycemic control.
GLP-1 receptor agonists offer significant cardiometabolic benefits, addressing inflammation and metabolic disturbances in obesity-related heart failure with preserved ejection fraction (HFpEF).
Pancreatic **pVHL** gene therapy via adenoviral vector cut blood glucose in hypercaloric diet-induced **Type 2 Diabetes Mellitus** mice.
A promising new direction emerges for treating **MC4R**-related **obesity**, a condition with limited therapeutic options. **SKNY-1**'s ability to address both metabolic dysfunction and maladaptive reward behaviors su…
Insulin and incretin receptor agonists (IRAs) reciprocally influence each other's blood-brain barrier permeability, suggesting complex interactions at this critical interface.
Free, no account — handy when you're working with Tirzepatide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account